TW200516081A - PTP1B anti-sense compounds - Google Patents
PTP1B anti-sense compoundsInfo
- Publication number
- TW200516081A TW200516081A TW093125691A TW93125691A TW200516081A TW 200516081 A TW200516081 A TW 200516081A TW 093125691 A TW093125691 A TW 093125691A TW 93125691 A TW93125691 A TW 93125691A TW 200516081 A TW200516081 A TW 200516081A
- Authority
- TW
- Taiwan
- Prior art keywords
- ptp1b
- different
- represent same
- sense compounds
- nonvel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A Nonvel PTP1B antisense compound and pharmacologically acceptable salt thereof of formula E1-B1-B2-B3-B4-B5-B6-B7-B8-B9-B10-B11-B12-B13-B14-B15-B16-E2 (l) (wherein, B1, B4, B5, B10, B13 and B16 represent same or different Tp and the lice, B11 represents Gp and the like, B2, B3, B6, B7, B9﹑B14, B15 represent same or different Cp and the like, B8, B12 represent same or different Ap and the like. E1 represents hydrogen group and the like, and E2-B23-R1 and the like) which inhibits the activity of PTPIB, and effectively treats the disease concerned with hyperactivity of tyrosine phosphorylation due to PTP1B.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003304489 | 2003-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200516081A true TW200516081A (en) | 2005-05-16 |
Family
ID=34269271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093125691A TW200516081A (en) | 2003-08-28 | 2004-08-27 | PTP1B anti-sense compounds |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW200516081A (en) |
WO (1) | WO2005021572A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2697244B1 (en) | 2011-04-13 | 2017-05-17 | Ionis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2489145A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | Insulin-sensitizing agent |
-
2004
- 2004-08-27 WO PCT/JP2004/012806 patent/WO2005021572A1/en active Application Filing
- 2004-08-27 TW TW093125691A patent/TW200516081A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005021572A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY140638A (en) | New heterocyclic compounds, which are active as inhibitors of beta-lactamases | |
MX2007013624A (en) | Protein kinase inhibitors. | |
TW200626068A (en) | Active compounds for seed treatment | |
TW200740434A (en) | A prophylactic and/or therapeutic agent for for sleep disorders | |
NO20062689L (en) | Azabicyclic heterocycles as modulators of cannabinoid receptors | |
WO2008005956A3 (en) | Pyrrolotriazine kinase inhibitors | |
IL179607A0 (en) | Indoles useful in the treatment of inflammation | |
MY153044A (en) | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders | |
UA84460C2 (en) | Use of sulphonylcarbamides for combating undesirable plant growth in leguminous plant cultures | |
MX2009005691A (en) | Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme. | |
IL179728A0 (en) | Indoles useful in the treatment of inflammation | |
MX2009002735A (en) | Oxindole derivatives. | |
DE602007011414D1 (en) | AGRICULTURAL CHEMICAL COMPOSITIONS WITH ALKYLENDIOL-MODIFIED POLYSILOXANES | |
BRPI0810641A2 (en) | "pharmaceutical compounds". | |
TW200744586A (en) | Therapeutic compounds | |
HK1091481A1 (en) | Therapeutic agents useful for treating pain | |
MX2010004312A (en) | Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity. | |
GEP20125538B (en) | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases | |
MY151295A (en) | Pyrimidyl indoline compound | |
BRPI0410649A (en) | substituted benzo (b) thiophene 3-aryloxy and 3-heteroaryloxy as therapeutic agents with pi3k activity | |
WO2006127379A3 (en) | Par2-modulating compounds and their use | |
PA8599701A1 (en) | DOSAGE FORMS AND TREATMENT PROCEDURES USING VEGFR INHIBITORS | |
NO20092035L (en) | Thiazolyl compounds useful as kinase inhibitors | |
TW200516081A (en) | PTP1B anti-sense compounds | |
TW200736236A (en) | Process for the manufacturing of pharmaceutically active compounds |